

All communications respecting this application should give the serial number, date of filing and name of the applicant.



U. S. DEPARTMENT OF COMMERCE
Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

Application Number	Filing Date	First Named Applicant	Attorney Docket Number
10/018,446	04/12/02	Zablocki	99,423-S

Examiner
L. E. Crane

Art Unit	Paper No.
1623	11

DATE MAILED: n/a

INTERVIEW SUMMARY

All participants (applicant, applicant's representative, PTO personnel)

(1) Mr. A. Blair Hughes (3) --
(2) Examiner L. E. Crane (4) --

Date of Interview: 05/14 & 19/03

Type: ☒ Telephonic ☐ Personal (copy given to) ☐ applicant ☐ applicant's representative

Exhibit shown or demonstration conducted: ☐ Yes ☒ No If yes, brief description: See attachment.

Agreement ☒ was reached with respect to some of all of the claims in question. ☐ was not reached

Claim(s) discussed: See page 2.

Identification of prior art discussed: See page 2.

Description of the general nature of what was agreed to if an agreement was reached, or any other comment: See p. 2.

(A fuller description, if necessary, and a copy of the amendments, if available, which the examiner agreed would be allowable must be attached. Also, where no copy of the amendments which would render the claims allowable is available, a summary thereof must be attached.)

1. ☒ It is not necessary for applicant to provide a separate record of the substance of the interview.

Unless the paragraph above has been checked to indicate to the contrary, A FORMAL RESPONSE TO THE LAST OFFICE ACTION IS NOT WAIVED AND MUST INCLUDE THE SUBSTANCE OF THE INTERVIEW. (See MPEP § 713.04) If a response to the last Office action has already been filed, APPLICANT IS GIVEN ONE MONTH FROM THIS INTERVIEW DATE TO FILE A STATEMENT OF THE SUBSTANCE OF THE INTERVIEW.

2. ☐ Since the Examiner's interview summary above (including any attachments) reflects a complete response to each of the objections, rejections and requirements that may be present in the last Office action, and since the claims are now allowable, the completed form is considered to fulfill the response requirements of the last Office action. Applicant is not relieved from providing a separate record of the interview unless box 1 above is also checked.

Examiner Note: You must sign this form unless it is an attachment to another form.

PTOL-413 (amended 03/13/01)

10/018,446 - P. N. 11

COPY FOR ☒ File ☐ Applicant

Continued on next page(s) ->>

Serial No. 10/018,446

2

Art Unit 1623

INTERVIEW SUMMARY(cont.)

Claims discussed: All remaining of record, claim 25 in particular.

Identification of prior art discussed: NONE.

Description of the general nature of what was agreed to if an agreement was reached, or any other comment: Applicant was advised that claim 20 needed to have the term "by" replaced by -- comprising --, and that claim 25 was not allowable because pharmaceutical claims may not be limited by method of treating limitations and therefore its cancellation by examiner's amendment was requested. Applicant agreed on condition that two new claims be added to claim methods of treating angioplasty and inhibiting platelet aggregation to which examiner agreed. Applicant then authorized the agreed to examiner's amendment, and was informed that the case as finally amended would be passed to issue in due course.